Extended adjuvant temozolomide with cis-retinoic acid for adult glioblastoma

Current Oncology

Volumn 19, Issue 6, 2012, Pages 308-314

  Pitz, M W ^a,b   Lipson, M ^c   Hosseini, B ^c   Lambert, P ^b   Guilbert, K ^a,b   Lister, D ^b   Schroeder, G ^b   Jones, K ^b   Mihalicioiu, C ^d   Eisenstat, D D ^a,e,f  

^a UNIVERSITY OF MANITOBA   (Canada)

^b CANCERCARE MANITOBA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e and Ophthalmology ^*  (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

cis retinoic acid; Dose density; Duration of therapy; Glioblastoma; Temozolomide

Indexed keywords

ANTIDEPRESSANT AGENT; ISOTRETINOIN; TEMOZOLOMIDE;

ACUTE LEUKEMIA; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANADA; CANCER ADJUVANT THERAPY; CANCER REGISTRY; CANCER SURVIVAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLIOBLASTOMA; HEALTH CARE QUALITY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; POPULATION RESEARCH; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA;

EID: 84870751802     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.1151     Document Type: Article

References (31)

1. Stupp R, Mason WP, van den Bent MJ, et al. on behalf of the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and the National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
2. Stupp R, Hegi ME, Mason WP, et al. on behalf of the European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups and the National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase iii study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
3. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20:1375-82.
4. Gilbert MR, Wang M, Aldape KA, et al. RTOG 0525: a randomized phase iii trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (DD) schedule in newly diagnosed glioblastoma (GBM) [abstract 2006]. J Clin Oncol 2011;29:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=79659; cited September 12, 2012]
5. Roldán Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme. J Neurooncol 2012;108:173-7.
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
7. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97.
8. André T, Boni C, Mounedji-Boudiaf L, et al. on behalf of the Multicenter International Study of Oxaliplatin/5-Fluorouracil/ Leucovorin in the Adjuvant Treatment of Colon Cancer(MOSAIC) investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.
9. National Comprehensive Cancer Network (NCCN). Breast Cancer. NCCN Clinical Practice Guidelines in Oncology. Ver. 3.2012. Fort Washington, PA: NCCN; 2012.
10. Taphoorn MJ, Stupp R, Coens C, et al. on behalf of the European Organisation for Research and Treatment of Cancer Brain Tumour Group, the EORTC Radiotherapy Group, and the National Cancer Institute of Canada Clinical Trials Group. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol 2005;6:937-44.
11. Osoba D, Brada M, Yung WK, Prados M. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 2000;18:1481-91.
12. Seiz M, Krafft U, Freyschlag CF, et al. Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution. J Cancer Res Clin Oncol 2010;136:1691-5.
13. Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology 2007;68:688-90.
14. Reboul P, George P, Louisot P, Broquet P. Study of retinoic acid effect upon retinoic acid receptors beta (rar-beta) in C6 cultured glioma cells. Biochem Mol Biol Int 1995;36:1097-105.
15. Bouterfa H, Picht T, Kess D, et al. Retinoids inhibit human glioma cell proliferation and migration in primary cell cultures but not in established cell lines. Neurosurgery 2000;46:419-30.
16. Rodts GE Jr, Black KL. Trans retinoic acid inhibits in vivo tumour growth of C6 glioma in rats: effect negatively influenced by nerve growth factor. Neurol Res 1994;16:184-6.
17. Das A, Banik NL, Ray SK. Retinoids induced astrocytic differentiation with down regulation of telomerase activity and enhanced sensitivity to taxol for apoptosis in human glioblastoma T98G and U87MG cells. J Neurooncol 2008;87:9-22.
18. Wismeth C, Hau P, Fabel K, et al. Maintenance therapy with 13-CIS retinoid acid in high-grade glioma at complete response after first-line multimodal therapy-a phase-ii study. J Neurooncol 2004;68:79-86.
19. Yung WK, Kyritsis AP, Gleason MJ, Levin VA. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Clin Cancer Res 1996;2:1931-5.
20. Clarke JL, Iwamoto FM, Sul J, et al. Randomized phase ii trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol 2009;27:3861-7.
21. Jaeckle KA, Hess KR, Yung WK, et al. Phase ii evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 2003;21:2305-11.
22. Butowski N, Prados MD, Lamborn KR, et al. A phase ii study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. Int J Radiat Oncol Biol Phys 2005;61:1454-9.
23. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase ii studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80.
24. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group. J Clin Oncol 2010;28:1963-72.
25. Dafni U. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes 2011;4:363-71.
26. Gerson SL, Miller K, Berger NA. O6-Alkylguanine-dna alkyltransferase activity in human myeloid cells. J Clin Invest 1985;76:2106-14.
27. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95:190-8.
28. Senft C, Franz K, Blasel S, et al. Influence of imri-guidance on the extent of resection and survival of patients with glioblastoma multiforme. Technol Cancer Res Treat 2010;9:339-46.
29. Li J, Wang M, Won M, et al. Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys 2011;81:623-30.
30. Sanai N, Berger MS. Operative techniques for gliomas and the value of extent of resection. Neurotherapeutics 2009;6:478-86.
31. Grossman SA, Ye X, Piantadosi S, et al. on behalf of the NABTT CNS Consortium. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 2010;16:2443-9.